Geneva, May 4 -- International Clinical Trials Registry received information related to the study (NCT07410507) titled 'A Study of Brenipatide in Adult Participants With Schizophrenia' on Feb. 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Eli Lilly and Company
Condition:
Schizophrenia
Intervention:
Drug: Brenipatide
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: February 10, 2026
Target Sample Size: 450
Countries of Recruitment:
United States
Argentina
Brazil
China
India
Japan
Taiwan
Argentina
Brazil
China
India
Japan
Taiwan
United States
To know...